English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The development of biosimilar medicines has been an innovative healthcare solution, as it has provided opportunities for biotechnological growth and advancement for the pharmaceutical industries, as well as new treatment options for cancer patients. HER2 is a clinically established therapeutic target in therapy against breast malignancy; it is estimated that HER2 overexpression occurs in approximately 20% of breast carcinoma cases; several biological drugs are under development, but currently only a few monoclonal antibodies have been authorized in Brazil for the treatment of HER2 positive breast cancer, including trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1) and CT-P6. With the approval of new molecules and the expiration of these drugs patents, there was an increase in biological product options available at potentially lower costs. The present study is a literature review that aims to address the biosimilar target therapy in the treatment of HER2 overexpressed breast cancer, which has one of the worst prognoses in relation to the other subtypes. Subsequently, we present studies on the clinical efficacy of ANVISA approved monoclonal antibodies. In conclusion, studies have proven the benefits of using biosimilars when added to adjuvant and neoadjuvant chemotherapy, significantly improving patient survival. The treatment for HER2-positive metastatic breast cancer has been developed with humanized monoclonal antibodies, which significantly increase the outcome and effectiveness of therapy, and due to the excellent results presented, new HER2-targeted drugs are under development.

Impacto de medicamentos biossimilares utilizados na imunoterapia contra o câncer de mama no Brasil